SCHEMBL13698393

SCHEMBL13698393

C[C@@H](C(CO)NS(=O)(=O)c1ccc(Cl)cc1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.48
CA1 P00915 5/20 0.48
PSEN1 P49768 2/20 0.46
PSEN2 P49810 2/20 0.46
APH1B Q8WW43 2/20 0.46
NCSTN Q92542 2/20 0.46
APH1A Q96BI3 2/20 0.46
PSENEN Q9NZ42 2/20 0.46
MMP2 P08253 6/20 0.46
MMP1 P03956 3/20 0.46
MMP9 P14780 3/20 0.46
MMP13 P45452 3/20 0.46
MMP3 P08254 2/20 0.46
MMP7 P09237 2/20 0.46
CA12 O43570 3/20 0.46
CA9 Q16790 3/20 0.46
CA14 Q9ULX7 3/20 0.46
MMP8 P22894 3/20 0.45
MMP14 P50281 1/20 0.45
CA3 P07451 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3904632 1.00 CA2 (0.48) CA2CA1PSEN1PSEN2APH1B
SCHEMBL3904712 1.00 CA2 (0.48) CA2CA1PSEN1PSEN2APH1B
SCHEMBL3915493 0.87 MMP1 (0.47) CA2CA1PSEN1PSEN2APH1B
SCHEMBL13790855 0.87 CA2 (0.57) CA2CA1MMP2MMP1MMP9
SCHEMBL3904707 0.86 CA1 (0.52) CA2CA1MMP2MMP1MMP9
SCHEMBL14401877 0.86 SMN1; SMN2 (0.48) CA2CA1PSEN1PSEN2APH1B
SCHEMBL3319698 0.86 PSEN1 (0.61) CA2CA1PSEN1PSEN2APH1B
SCHEMBL3906259 0.86 PSEN1 (0.61) CA2CA1PSEN1PSEN2APH1B
SCHEMBL3906410 0.85 RAB9A (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3177089 0.84 MMP2 (0.55) CA2CA1MMP2MMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221711-A1 TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS WYETH (US) 2009-09-03 US disclosed
US-20090221711-A1 TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS WYETH (US) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221711-A1 TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS APP, PSEN1, BACE1 CA2 3338/4885CA1 1419/4885PSEN1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.